Aktienanalyse zu Actuate Therapeutics Inc (ACTU)ACTUActuate Therapeutics Inc

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. It operates in the Healthcare sector.

Actuate Therapeutics Inc (ACTU) appears to be a good buy right now due to its recent positive clinical trial results, which have driven a 30.31% increase in stock price over the last five days. The stock is currently priced at $1.66, with a projected trajectory suggesting a potential increase of 163.80% based on historical patterns. However, the company has reported significant net losses, with a net income of -5,626,749 USD in Q1 2026, indicating ongoing financial challenges. The main risk is its high volatility, as evidenced by a year-to-date change of -72.55%.